CLEARWATER, Fla. — November 18, 2025 — Leads & Copy — Apyx Medical Corporation (Nasdaq: APYX) announced the pricing of its underwritten public offering of 2,762,431 shares of common stock at $3.62 per share, before underwriting discounts, commissions, and offering expenses.
Lucid Capital Markets is the sole book-running manager for the offering. All shares in the offering will be sold by Apyx Medical. The company has granted the underwriter a 45-day option to purchase up to 414,365 additional shares of common stock at the public offering price, minus underwriting discounts and commissions.
The offering is expected to close around November 19, 2025, pending customary closing conditions. Apyx Medical intends to use the net proceeds for working capital and general corporate purposes.
The offering is made under a shelf registration statement on Form S-3 (File No. 333-268532) filed with the SEC on November 22, 2022, and declared effective on December 2, 2022.
A preliminary prospectus supplement and accompanying prospectus are filed with the SEC and available on its website. A final prospectus supplement will also be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus can be obtained from Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.
This press release does not offer to sell or solicit offers to buy securities in any jurisdiction where such action would be unlawful before registration or qualification under securities laws.
Apyx Medical Corporation is a surgical aesthetics company passionate about elevating people’s lives through innovative products. These include its Helium Plasma Platform Technology products marketed as Renuvion® and the AYON Body Contouring System™ (AYON) in cosmetic surgery, and J-Plasma® in the hospital surgical market. These products offer surgeons controlled heat to tissue to achieve desired results.
The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical documents. The AYON Body Contouring System™ is an FDA-cleared body contouring system that combines precision, versatility, and innovation, integrating fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities. The Company leverages its expertise in unique waveforms through OEM agreements with other medical device manufacturers.
Investor Relations Contact:
Jeremy Feffer, Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
Source: Apyx Medical Corporation
Source: Apyx Medical Corporation
